Line 71: | Line 71: | ||
<p><br>Romel is a Biomedical Engineering PhD student. Originally from Peru, he came to the US to the University of South Carolina to earn a BS degree in Biomedical Engineering in 2009. He started his graduate studies at Duke in 2013 and joined the Lynch Lab in 2015. His project involves developing a platform for in vivo peptide lipidation for novel materials and pharmaceuticals</p> | <p><br>Romel is a Biomedical Engineering PhD student. Originally from Peru, he came to the US to the University of South Carolina to earn a BS degree in Biomedical Engineering in 2009. He started his graduate studies at Duke in 2013 and joined the Lynch Lab in 2015. His project involves developing a platform for in vivo peptide lipidation for novel materials and pharmaceuticals</p> | ||
</td> | </td> | ||
− | <td align="center"><img src="https:// | + | <td align="center"><img src="https://static.igem.org/mediawiki/2018/e/ef/T--Duke--Romel.png" style="width:243px;height:263px;"></td> |
</tr> | </tr> | ||
Revision as of 19:28, 13 October 2018
Our Advisors
Advisors
Michael Lynch
|
|
Adim Moreb
|
|
John Decker
|
|
Romel Menacho-Melgar
|